Tonix Pharmaceuticals Announces Positive Phase 3 RELIEF Study Results for TNX-102 SL 5.6 mg in Fibromyalgia
December 07, 2020 07:00 ET
|
Tonix Pharmaceuticals Holding Corp.
New 5.6 mg Dose Achieved Statistically Significant Pain Reduction Over Placebo at Week 14 (Primary Endpoint, p=0.01) TNX-102 SL Generally Well Tolerated with Adverse Event Profile Comparable to...
Vaccine Genome Researchers Report 99.7% Colinear Identity Between a U.S. Civil War Era Smallpox Vaccine and Horsepox Virus
December 04, 2020 08:00 ET
|
Tonix Pharmaceuticals Holding Corp.
Findings Published in the Current Issue of the Journal Genome Biology Horsepox is the Vector for Tonix’s Experimental TNX-1800 COVID-19 Vaccine Horsepox Has Been Used as a Smallpox Vaccine Since...
Tonix Pharmaceuticals Reports Positive Immune Response Results from COVID-19 Vaccine Candidate TNX-1800, Following Vaccination of Non-Human Primates
November 16, 2020 07:00 ET
|
Tonix Pharmaceuticals Holding Corp.
Anti-SARS-CoV-2 Neutralizing Antibodies Elicited in All Eight TNX-1800 Vaccinated Animals Skin Reaction or “Take,” a Validated Biomarker of Functional T cell Immunity, Elicited in All Eight TNX-1800...
Tonix Pharmaceuticals Outlines New Statistical Method to Analyze Future PTSD Studies at the 3rd Annual Neuropsychiatric Drug Development Summit
November 12, 2020 16:32 ET
|
Tonix Pharmaceuticals Holding Corp.
Increasing Placebo Responses in PTSD Drug Trials Raise Questions About Current Methods of Measuring or Analyzing PTSD Symptom Change Over Time The U.S. 21st Century Cures Act Provides Direction on...
Tonix Pharmaceuticals to Participate in Upcoming November Conferences
November 11, 2020 07:00 ET
|
Tonix Pharmaceuticals Holding Corp.
CHATHAM, N.J., Nov. 11, 2020 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP) (Tonix or the Company), a clinical-stage biopharmaceutical company, announced today that Seth...
Tonix Pharmaceuticals to Present at 3rd Annual Neuropsychiatric Drug Development Summit
November 09, 2020 16:15 ET
|
Tonix Pharmaceuticals Holding Corp.
CHATHAM, N.J., Nov. 09, 2020 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP) (Tonix or the Company), a clinical-stage biopharmaceutical company, announced today that Seth...
Tonix Pharmaceuticals Reports Third Quarter 2020 Financial Results and Operational Highlights
November 09, 2020 08:30 ET
|
Tonix Pharmaceuticals Holding Corp.
Data from Animal Studies of COVID-19 Vaccine Candidate, TNX-1800, Expected in Fourth Quarter 2020 Phase 1 Safety Study in Humans of TNX-1800 Expected to be Initiated in 2021 CHATHAM, N.J., Nov. ...
Tonix Pharmaceuticals Enrolls First Participant in the PRECISION Study, an Observational Study to Facilitate Development of Precision Medicine Techniques for COVID-19 Vaccines and Therapeutics
October 15, 2020 07:00 ET
|
Tonix Pharmaceuticals Holding Corp.
Study May Lead to Biomarkers for Tailoring COVID-19 Vaccines and Therapeutics Potential Development of Human Monoclonal Antibody Therapeutics to SARS-CoV-2 Results from the PRECISION Study Expected...
Tonix Pharmaceuticals to Participate in BIO Investor Forum Digital
October 07, 2020 07:00 ET
|
Tonix Pharmaceuticals Holding Corp.
CHATHAM, N.J., Oct. 07, 2020 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP) (Tonix or the Company), a clinical-stage biopharmaceutical company, announced today that Seth...
Tonix Pharmaceuticals Announces Plan to Complete the Phase 3 RELIEF Study of TNX-102 SL for Management of Fibromyalgia with Currently Enrolled Participants Based on Results of Interim Analysis
September 29, 2020 16:05 ET
|
Tonix Pharmaceuticals Holding Corp.
Topline Results of Full Study Expected Fourth Quarter 2020 RELIEF Study Protocol Was Formally Amended Mid-Study to Conform to FDA Guidance During COVID-19 Public Health Emergency Currently Enrolled...